KoBioLabs Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 51

Employees

  • Stock Symbol
  • 348150

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $3.33
  • (As of Friday Closing)

KoBioLabs General Information

Description

KoBioLabs Inc is a biotechnology company focused on Microbiome therapeutics. It is involved in the research of medicines for Immune, Metabolic and Neurological Diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 7F, Building C, Daewangpangyo-ro
  • Bundang-gu
  • Seongnam-si, Gyeonggi-do 13488
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
KRX
Vertical(s)
LOHAS & Wellness, Life Sciences
Corporate Office
  • 7F, Building C, Daewangpangyo-ro
  • Bundang-gu
  • Seongnam-si, Gyeonggi-do 13488
  • South Korea
+82

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

KoBioLabs Stock Performance

As of 07-Feb-2025, KoBioLabs’s stock price is $3.33. Its current market cap is $64.6M with 19.3M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.33 $3.41 $3.14 - $7.62 $64.6M 19.3M 61K -$0.37

KoBioLabs Financials Summary

As of 30-Sep-2024, KoBioLabs has a trailing 12-month revenue of $45.6M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 78,737 95,943 104,748 215,594
Revenue 45,552 25,346 8,982 2,526
EBITDA (6,070) (11,387) (17,470) (14,390)
Net Income (7,039) (10,595) (16,965) (13,429)
Total Assets 79,610 88,946 98,130 88,474
Total Debt 12,585 14,196 10,913 7,728
Public Fundamental Data provided by Morningstar, Inc. disclaimer

KoBioLabs Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore KoBioLabs‘s full profile, request access.

Request a free trial

KoBioLabs Patents

KoBioLabs Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230293600-A1 Faecalibacterium prausnitzii strain and uses there of Pending 14-Aug-2020
EP-4201415-A1 Faecalibacterium prausnitzii strain and uses thereof Pending 14-Aug-2020
EP-4201415-A4 Faecalibacterium prausnitzii strain and uses thereof Pending 14-Aug-2020
US-20230173019-A1 Protein variant having glp-1 inducing activity and use thereof Pending 24-Apr-2020
EP-4141023-A1 Protein variant having glp-1 inducing activity and use thereof Pending 24-Apr-2020 A61K38/16
To view KoBioLabs’s complete patent history, request access »

KoBioLabs Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

KoBioLabs Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore KoBioLabs‘s full profile, request access.

Request a free trial

KoBioLabs Investments (1)

KoBioLabs’s most recent deal was a Joint Venture with WeBiom. The deal was made on 01-Mar-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
WeBiom 01-Mar-2022 Joint Venture Pharmaceuticals
To view KoBioLabs’s complete investments history, request access »

KoBioLabs ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

38.04 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,784

Rank

Percentile

Pharmaceuticals

Industry

of 955

Rank

Percentile

Biotechnology

Subindustry

of 440

Rank

Percentile

To view KoBioLabs’s complete esg history, request access »

KoBioLabs FAQs

  • When was KoBioLabs founded?

    KoBioLabs was founded in 2014.

  • Where is KoBioLabs headquartered?

    KoBioLabs is headquartered in Seongnam-si, South Korea.

  • What is the size of KoBioLabs?

    KoBioLabs has 51 total employees.

  • What industry is KoBioLabs in?

    KoBioLabs’s primary industry is Drug Discovery.

  • Is KoBioLabs a private or public company?

    KoBioLabs is a Public company.

  • What is KoBioLabs’s stock symbol?

    The ticker symbol for KoBioLabs is 348150.

  • What is the current stock price of KoBioLabs?

    As of 07-Feb-2025 the stock price of KoBioLabs is $3.33.

  • What is the current market cap of KoBioLabs?

    The current market capitalization of KoBioLabs is $64.6M.

  • What is KoBioLabs’s current revenue?

    The trailing twelve month revenue for KoBioLabs is $45.6M.

  • What is KoBioLabs’s annual earnings per share (EPS)?

    KoBioLabs’s EPS for 12 months was -$0.37.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »